# A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)

> **NCT00002014** · PHASE1 · COMPLETED · sponsor: **Glaxo Wellcome**

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Zidovudine
- **DRUG:** Didanosine

## Key facts

- **NCT ID:** NCT00002014
- **Lead sponsor:** Glaxo Wellcome
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002014, "A Phase I Study to Evaluate the Pharmacokinetics, Safety and Antiviral Effects of Concurrent Administration of Zidovudine (AZT) and 2'3'-Dideoxyinosine (ddI) in Patients With Human Immunodeficiency Virus (HIV)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*